On Wednesday, Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI)’s shares declined -3.51% to $7.42.
Plasmatech Biopharmaceuticals Inc (PTBI) accomplished its acquisition of Abeona Therapeutics LLC, an Ohio limited liability company (“Abeona”) following the terms of a contract and Plan of Merger, dated as of May 5, 2015, the execution of which was formerly revealed in a Current Report on Form 8-K filed by PlasmaTech on May 6, 2015 (the “Acquisition”).
In connection with the Acquisition, PlasmaTech will issue an aggregate of 3,979,761 shares of PlasmaTech’s common stock to the members of Abeona. In addition, there may be up to an additional $9 million in performance milestones payable to members of Abeona, in common stock or cash, at PlasmaTech’s option.
PlasmaTech will file with the Securities and Exchange Commission (the “SEC”) the financial statements and pro forma financial information required to be filed following Rule 3-05 of Regulation S-X and Article 11 of Regulation S-X within 71 days after the date on which this Current Report on Form 8-K was required to be filed with the SEC.
PlasmaTech Biopharmaceuticals, Inc. operates as a biopharmaceutical company and develops protein biologic therapies and oncology supportive care products. The companys marketed product comprises MuGard the administration of oral mucositis; and ProctiGard for the treatment of radiation proctitis, a frequent side effect of radiation treatment to the pelvic region.
Hanwha Q Cells Co Ltd –ADR (NASDAQ:HQCL)’s shares dropped -14.49% to $1.50.
Hanwha Q Cells Co Ltd –ADR (HQCL) declared that it will change the ratio of its American Depositary Shares (“ADSs”) to ordinary shares from one (1) ADS representing five (5) ordinary shares to one (1) ADS representing fifty (50) ordinary shares, effective on June 15, 2015.
Each shareholder of record at the close of business on June 12, 2015 will be required to exchange every ten (10) ADSs then held for one (1) new ADS. The effect on the ADS price will take place on June 15, 2015.
Hanwha Q CELLS Co., Ltd., a solar energy company, develops, manufactures, and sells solar cells and photovoltaic (PV) modules in Europe, North America, Asia, South America, Africa, and the Middle East. Its products and services comprise PV modules, PV cells, silicon ingots, and silicon wafers.
At the end of Wednesday’s trade, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)‘s shares surged 2.89% to $11.76.
Vanda Pharmaceuticals Inc. (VNDA) declared that it has received the 2015 Industry Innovation Award from the National Organization of Rare Disorders (NORD) in recognition of Vanda’s work in developing HETLIOZ® (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). This award was presented to Vanda at the 2015 Portraits of Courage Gala in Washington D.C. on May 18th.
HETLIOZ® was approved by the U.S. for the treatment of Non-24 in January of 2014. In April 2015, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for HETLIOZ® for the treatment of Non-24. A final decision is predictable by the end of the second quarter of 2015.
Established in 1983, NORD is the primary nonprofit organization representing all patients and families affected by rare diseases in the U.S. NORD is committed to the identification, treatment and cure for all 7,000 rare diseases that affect 30 million Americans. NORD provides programs of advocacy, education, research and patient/family services to improve the lives of all people living with rare diseases.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company’s products comprise HETLIOZ, a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a product for the treatment of schizophrenia. Its products also comprise Tradipitant, a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis; Trichostatin A, a small molecule histone deacetylase inhibitor; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), ended its Wednesday’s trading session with -1.34% loss, and closed at $19.13.
Aegerion Pharmaceuticals, Inc. (AEGR) declared the primary endpoint was achieved in the Company’s open-label, multicenter study to evaluate the efficacy and safety of lomitapide in nine Japanese patients with homozygous familial hypercholesterolemia (HoFH). The primary endpoint measured mean percent change in low-density lipoprotein cholesterol (LDL-C) at the maximum tolerated dose contrast to baseline after 26 weeks of treatment, in combination with other lipid-lowering therapy.
Following the 26 week assessment, patients in the study entered a 30-week safety phase. Each patient will continue receiving the maximum tolerated dose of lomitapide he or she achieved during the efficacy phase for an additional 30 weeks in the safety phase, subject to safety-related dose adjustments. The Company anticipates to file the NDA in Japan with the 26-week data, and to submit the 56-week data during the review cycle.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products comprise JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments, counting low-density lipoprotein, low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia (HoFH); and LOJUXTA (lomitapide) hard capsule used as a treatment for HoFH in adults. Its products also comprise MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or attained generalized lipodystrophy.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
